Our team brings together decades of experience in AD with the singular goal of easing the devastation it causes. We’ve made it our mission, because we know someone too.
SHARON L. ROGERS, PH.D.
CHIEF EXECUTIVE OFFICER
Sharon brings the strength behind 35 years of pharma experience to AMYRIAD. She is best known as the worldwide leader and development strategist for the highly successful AD treatment, Aricept. Aricept has been the standard of care for more than 20 years and no other AD program has produced more compelling results.
Sharon has perspectives from large-cap to VC-incubated companies. Her first start-up was Eisai’s fledgling US subsidiary. She rose to VP of CR&D and later extended her reach at Eisai’s Tokyo headquarters as Global Director of Strategic Portfolio Management and Vice Chair of the Global Clinical Committee. Upon returning from Japan, she moved to VC-based start-ups holding a variety of senior executive positions, including CEO, CMO and President.
Sharon earned her B.A. from Capital University and a Ph.D. from the Ohio State University College of Medicine, School of Biomedical Sciences. She has been a lifetime entrepreneur, starting her first enterprise while still in graduate school. Outside of business, she enjoys cycling and long-distance running, with over a dozen marathons under her belt. She also has served the United States as a distinguished Olympic and World Championship judge of Figure Skating.
“I work with superb colleagues in one of the most compelling areas of medicine imaginable. AD patients deserve treatments that provide meaningful improvement in their lives. Until we have them, our job is not done.”
GALIT A. YAAKOBOVITZ, MBA, CPA
CHIEF FINANCIAL OFFICER
Galit brings AMYRIAD more than 20 years of senior executive experience in finance, accounting, fund raising and infrastructure creation. She enjoys working with fast-moving biotech start-ups and leading financial efforts that support private to public transition.
After receiving a dual-major B.S. in Accounting, Statistics and Operations Research at Tel Aviv University, Galit began developing her craft at BDO, working with both public and private companies. She gained strong expertise in GAAP, SOX and on a variety of audit and compliance issues. Seeing firsthand the critical role financial operations and infrastructure play in company success, she obtained her M.B.A. from Tel Aviv University and moved into financial strategy. Galit has devoted the last decade to biotech, first at Compugen USA and most recently as VP of Finance and Operations at Arch Oncology.
In her outside life, Galit relishes the company of family and friends. She is an avid hiker, backpacker and Pilates practitioner.
“I am excited to be part of the inspiring and collaborative AMYRIAD team. Life expectancy increases every year and people deserve to maintain quality of life as they age.”
YOSHIKO STOWELL, PhD
Vice President of Regulatory Affairs
Yoshiko brings over 17 years of pharmaceutical industry experience to AMYRIAD. She started her career as a formulation scientist at Alza corporation. She worked on the development of a weekly Aricept patch for the treatment of Alzheimer’s Disease (AD) at Teikoku Pharma USA. She then transitioned to Clinical and Regulatory Affairs at Impax Pharmaceuticals, Inc. She most recently worked as a Senior Director of Regulatory Affairs at Eidos Therapeutics, Inc., a subsidiary of BridgeBio.
Yoshiko earned a B.S. in Chemistry from Tokyo University of Science, an M.S. degree in Chemical Engineering from University of Oklahoma, and a Ph.D. in Pharmaceutical Science from University of the Pacific. Outside of work, Yoshiko enjoys spending time with her three daughters, cooking, and gardening. She is an active member of Women in Bio.
“I joined AMYRIAD because I am honored to be part of a company that is developing better treatment options for patients with AD. Having cared for family members with AD, I personally feel passionate about helping patients with AD.”
PAUL JAROSZ, PhD
Vice President, CMC
Paul is a true CMC professional bringing over 30 years of experience moving a molecule from an idea to a commercial grade pharmaceutical product. Working with start-ups to large cap pharma companies Paul has been responsible for more than 65 entities launched in the US and EU, including solid, parenteral, and transdermal formulations for small through large molecules. He has contributed to CMC success for Sandoz, Ortho, Geneva and Roche Bioscience.
Paul received his Ph.D. in Pharmaceutics from the University of Iowa, his B.S. in Pharmacy from the University of Nebraska Medical Center and is an alumnus of the Harvard-Novartis Executive Development Program. He continues to share his commitment to pharmaceutical excellence as a reviewer for J. Pharmaceutical Science, Int. J. of Pharmaceutics, J. of Pharmaceutics and Biomedical Analysis and J. of Pharmaceutical Development and Technology.
JAN BURMEISTER, M.D.
Jan joins AmyriAD after a decade as a clinician/researcher in Neurology and Psychiatry. He received his medical degree from the University of Münster, Germany, and followed with a residency in neurology at University Hospital Essen where he conducted research and clinical trials at the University Duisburg-Essen. Throughout his clinical experience, Jan has worked closely with AD patients at all stages of the disease.
For his research, he received the Top Young Scientist Award from the German Society for Pain Therapy in 2017.
CHAZ de NARANJO
CLINICAL OPERATIONS DIRECTOR
Chaz joins Amyriad with over 12 years of experience in the cross-functional discipline of Clinical Operations. He specializes in strategic program planning and execution with experience in Phase 1 through Phase 3 programs in both the US and globally. He received his BS degree with an emphasis in neuroscience from UC Irvine, where he also earned a concurrent BA with a focus on law and society.
Chaz activities revolve around his children and volunteer work in his community. He also enjoys mountain biking, reading and drawing.
Megin is a top performing accounting and finance professional with more than 20 years of experience in both public and private companies. Megin has strong expertise in SOX compliance, GAAP and Netsuite. She was integral to creation of financial processes critical for private to public transition via IPO and contributed to the success of Yelp, Arch Oncology, Clorox International and Charles Schwab.
Megin received her Summa Cum Laude Bachelor of Science in Business Administration from California State University Hayward.
ANIL K. RATTY, PH.D.
Anil is a born entrepreneur and the key driver who brought AMYRIAD into being. He avidly follows everything in the biotech sector keeping his eye out for untapped potential. He has held positions as Chairman, Executive Director and CEO of a variety of venture-funded companies, many of which he founded.
Anil began his business career by establishing a biotech unit for Fisher Scientific (SEA) Pte. Ltd., and was later CEO for Cicada Cube, Pte Ltd. and Chief Scientific Officer for Cerca Insights. Anil’s first company as a founder was Chakra Biotech, focused on mental health. Part of Chakra was spun-off to form Cerca Insights, after which he created Cennerv Pharma and Argon Rede, Pte. Both Amyriad Therapeutics is his most recent venture.
Anil earned B.S. and Ph.D. degrees in Biochemistry from the National University of Singapore.
Anil receives tremendous joy from his wife and three children. He is an avid oil painter, a practitioner of Shitoryu Karate and a perpetual student. He lives to ride, never straying too far from his Harley.
“Memories are the essence of being a person and we need to do all we can to keep them.”
BOARD OF DIRECTORS
K. RANGA RAMA KRISHNAN, MB, CHB
CHAIRMAN OF THE BOARD
In addition to his position at the helm of AMYRIAD’s Board of Directors, Ranga serves as the CEO of the Rush University System for Health. It was a natural progression for this distinguished professional whose life has been one of entrepreneurship combined with dedication to finding health care solutions for patients and their families. Prior to joining Rush, Ranga served for as Founder and Dean of the Duke-NUS Graduate Medical School Singapore, a joint venture between Duke University and the National University of Singapore. For his service to Singapore, he received the Public Service Medal from the president of Singapore.
ARTHUR KLAUSNER, MBA
An experienced life science venture capitalist and company executive, Arthur is the Co-founder, President and Chief Executive Officer of Goldilocks Therapeutics, a company deploying mesoscale nanoparticles (MNPs) in the treatment of kidney disease. Prior to his operating roles, he spent 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. He currently serves on the Life Sciences Investment Review Board for the New York University Innovation Venture Fund. Arthur earned his M.B.A, from the Stanford University School of Business and a B.A. in Biology from Princeton University.
SRINIVAS RAO, M.D., PH.D.
Srinivas Rao is the Chief Scientific Officer at atai Life Sciences, N.V. He has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Srini has held the titles of Chief Scientific, Medical or Executive Officer at companies ranging from venture-backed startups to vertically-integrated, publicly traded pharmaceutical companies.
Srini earned both B.S. and M.Sc. degrees in Electrical Engineering from Yale College and Yale Graduate School, respectively. He received his Ph.D. in Neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. Srini completed an internship in Internal Medicine at Yale-New Haven Hospital.
ANIL K. RATTY, PH.D.
EXECUTIVE DIRECTOR OF THE BOARD
Anil is the founder and inspiration behind the creation of AMYRIAD. As a lifetime entrepreneur, he brings both a creative spark and valuable experience to our Board of Directors. Anil has guided a multitude of companies, both as an investor and as a member of key leadership, serving as Executive Director, Chief Science Officer, Chief Executive Officer and Chairman.
SHARON L. ROGERS, PhD
EXECUTIVE DIRECTOR OF THE BOARD
Sharon brings the strength of decades of successful pharma achievements to AMYRIAD. She is dedicated to creating a company of passionate high achievers that is innovative, structurally sound and with a vibrant, diverse and welcoming corporate culture.
Dr. Marlon Braumann
HOWARD FILLIT, M.D.
Howard Fillit, MD, is a geriatrician, neuroscientist, and innovative philanthropy executive, who has led the Alzheimer’s Drug Discovery Foundation as Executive Director since its inception. He has dedicated himself to the management of AD.
Howard is a Clinical Professor of Geriatric Medicine, Palliative Care and Neuroscience at the Icahn School of Medicine of Mount Sinai Medical Center in New York. He has also held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. He earned his B.A. in Neurobiology from Cornell University and his M.D. from the SUNY-Upstate Medical University.
SERGE GAUTHIER, C.M., M.D., FRCPC
Serge is the Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging and Douglas Research Centre. He also is Professor of the Departments of Neurology, Neurosurgery and Psychiatry at McGill University.
His contributions to AD are vast and it is unlikely there has been a significant clinical trial in AD in which Serge has not been an active investigator and/or collaborator. His special interests include ethical research practices in AD clinical trials, building a consensus approach to the management of AD during its different stages and prevention strategies against cognitive decline. Serge received his M.D. from the Université de Montréal.
RICHARD C. MOHS, PH.D.
Richard is Chief Scientific Officer for the Global Alzheimer’s Platform Foundation, a nonprofit working to improve the speed and quality of drug development for AD. He is well known for his collaboration with psychologist Wilma Rosen, Ph.D. and their creation of the Alzheimer’s Disease Assessment Scale, a tool that has been a mainstay of drug development trials for more than 25 years.
Richard received his B.S. in Psychology from the College of William & Mary and his Ph.D. in Mathematical Psychology from Stanford University. Prior to a distinguished career as VP for Neuroscience at Eli Lilly and Co., he was Professor of Psychiatry at Mount Sinai School of Medicine and Associate Chief of Staff for R&D at the Bronx VA Medical Center.